Enanta Pharmaceuticals, Inc.
ENTANASDAQHealthcareBiotechnology
Previous close
$13.47
+$0.34 · +2.59%
ENTA company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Hold
Wait — insufficient conviction to act
Valuation
55
Fair Value
Momentum
49
Neutral
Sentiment
57
Mixed
Risk resilience
47
Elevated Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteEnanta Pharmaceuticals, Inc. is a biotechnology firm dedicated to discovering and advancing small molecule therapies designed to combat a range of viral infections and various liver conditions. Its research and development efforts are primarily focused on addressing pathogens such as respiratory syncytial virus (RSV), SARS-CoV-2, human metapneumovirus (hMPV), and the hepatitis B virus (HBV). The company also holds a strategic partnership and licensing agreement with Abbott Laboratories. This collaboration involves the joint identification, development, and market introduction of specific HCV NS3 and NS3/4A protease inhibitor compounds, including known agents like paritaprevir and glecaprevir, which are utilized in the management of chronic hepatitis C virus. Founded in 1995, Enanta Pharmaceuticals, Inc. operates from its principal office located in Watertown, Massachusetts.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Jay R. Luly
- Listed since
- Mar 21, 2013
- Employees
- 120
Market position
Day range
Current $13.47
52-week range
Current $13.47
- Open
- $13.27
- Previous close
- $13.13
- Volume
- 335.25K
- 1.68× average
- Average volume
- 200.15K
- Average daily volume
- Market cap
- 391.69M USD
- Beta
- 0.93
- Market reference 1
- 50-day average
- $13.3388
- +0.98% above average
- 200-day average
- $13.4943
- -0.18% below average
Earnings
- EPS beat rate
- 55%
- 6 beats, 5 misses, 0 met estimates
- Average EPS surprise
- +1.44%
- 11 comparable reports
- Latest EPS result
- -0.67
- Estimate -0.51 · Miss by 31.50%
EPS: actual versus estimate
Recent quarterly results
Revenue: actual versus estimate
Recent quarterly results
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Analyst price target
Average target
$20.00
48.48% upsideRating distribution
19 ratingsENTA peers
ETFs holding ENTA
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI11.05M0.00%2.3T USD0.03%$378.24+0.44%
iShares Russell 2000 ETFIWM9.51M0.01%81.62B USD0.19%$299.96+0.77%
Vanguard Extended Market ETFVXF3.89M0.00%93.7B USD0.05%$245.53+0.82%
iShares Biotechnology ETFIBB2.69M0.03%10.75B USD0.44%$213.56+1.29%
Vanguard Russell 2000 ETFVTWO2.01M0.01%17.4B USD0.06%$121.25+0.74%
iShares Russell 2000 Value ETFIWN1.79M0.01%14.66B USD0.24%$224.81+0.45%
iShares Russell 2000 Growth ETFIWO1.7M0.01%15.16B USD0.24%$387.37+1.24%
Schwab U.S. Small-Cap ETFSCHA1.68M0.01%23.1B USD0.03%$34.83+0.52%Vanguard Morningstar Total Stock Market ETFVTI- Market value
- 11.05M
- Weight
- 0.00%
- AUM
- 2.3T USD
- Expense ratio
- 0.03%
- Price / 1D
- $378.24+0.44%
iShares Russell 2000 ETFIWM- Market value
- 9.51M
- Weight
- 0.01%
- AUM
- 81.62B USD
- Expense ratio
- 0.19%
- Price / 1D
- $299.96+0.77%
Vanguard Extended Market ETFVXF- Market value
- 3.89M
- Weight
- 0.00%
- AUM
- 93.7B USD
- Expense ratio
- 0.05%
- Price / 1D
- $245.53+0.82%
iShares Biotechnology ETFIBB- Market value
- 2.69M
- Weight
- 0.03%
- AUM
- 10.75B USD
- Expense ratio
- 0.44%
- Price / 1D
- $213.56+1.29%
Vanguard Russell 2000 ETFVTWO- Market value
- 2.01M
- Weight
- 0.01%
- AUM
- 17.4B USD
- Expense ratio
- 0.06%
- Price / 1D
- $121.25+0.74%
iShares Russell 2000 Value ETFIWN- Market value
- 1.79M
- Weight
- 0.01%
- AUM
- 14.66B USD
- Expense ratio
- 0.24%
- Price / 1D
- $224.81+0.45%
iShares Russell 2000 Growth ETFIWO- Market value
- 1.7M
- Weight
- 0.01%
- AUM
- 15.16B USD
- Expense ratio
- 0.24%
- Price / 1D
- $387.37+1.24%
Schwab U.S. Small-Cap ETFSCHA- Market value
- 1.68M
- Weight
- 0.01%
- AUM
- 23.1B USD
- Expense ratio
- 0.03%
- Price / 1D
- $34.83+0.52%
Continue in GoAI
Research ENTAresearch.disclaimer